Michael Bates

4.3k total citations
96 papers, 2.8k citations indexed

About

Michael Bates is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Infectious Diseases. According to data from OpenAlex, Michael Bates has authored 96 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 21 papers in Radiology, Nuclear Medicine and Imaging and 19 papers in Infectious Diseases. Recurrent topics in Michael Bates's work include HER2/EGFR in Cancer Research (27 papers), HIV/AIDS drug development and treatment (19 papers) and Monoclonal and Polyclonal Antibodies Research (18 papers). Michael Bates is often cited by papers focused on HER2/EGFR in Cancer Research (27 papers), HIV/AIDS drug development and treatment (19 papers) and Monoclonal and Polyclonal Antibodies Research (18 papers). Michael Bates collaborates with scholars based in United States, Austria and Belgium. Michael Bates's co-authors include Lee M. Nadler, S F Schlossman, Michael J. Furlong, K. C. Anderson, Gemma Pidelaserra-Martí, J F Daley, Eui Kyun Park, Nicholas S. Hellmann, Jodi Weidler and Christopher A. Kearney and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Bates

90 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Bates United States 28 686 660 639 559 531 96 2.8k
Jōhn W. Parker United States 32 177 0.3× 247 0.4× 549 0.9× 242 0.4× 721 1.4× 108 3.1k
Barry Anderson United States 21 501 0.7× 451 0.7× 818 1.3× 86 0.2× 345 0.6× 91 3.3k
J L Sullivan United States 22 1.0k 1.5× 899 1.4× 474 0.7× 55 0.1× 1.3k 2.5× 37 3.3k
Eva Halapi Sweden 25 388 0.6× 380 0.6× 294 0.5× 83 0.1× 894 1.7× 57 1.9k
David J. DiLillo United States 30 477 0.7× 142 0.2× 937 1.5× 1.6k 2.8× 3.8k 7.1× 50 6.3k
M. Jean Gilbert United States 23 330 0.5× 368 0.6× 860 1.3× 40 0.1× 1.3k 2.5× 42 3.5k
Sophia Lee United States 21 455 0.7× 293 0.4× 762 1.2× 112 0.2× 325 0.6× 61 2.5k
Alison Crawford United States 18 167 0.2× 104 0.2× 882 1.4× 71 0.1× 2.1k 4.0× 33 3.1k
Musie Ghebremichael United States 34 867 1.3× 924 1.4× 477 0.7× 161 0.3× 1.2k 2.2× 115 3.9k
Helen Brown Canada 27 325 0.5× 284 0.4× 1.2k 1.8× 38 0.1× 204 0.4× 93 2.8k

Countries citing papers authored by Michael Bates

Since Specialization
Citations

This map shows the geographic impact of Michael Bates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bates more than expected).

Fields of papers citing papers by Michael Bates

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bates. The network helps show where Michael Bates may publish in the future.

Co-authorship network of co-authors of Michael Bates

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bates. A scholar is included among the top collaborators of Michael Bates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bates. Michael Bates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goebell, Peter J., Ellen E. Paxinos, Jack Chen, et al.. (2024). Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study. Bladder Cancer. 10(1). 25–33.
2.
Bates, Michael, et al.. (2023). Development of a Fast and Quantitative FLT3-TKD Mutation Prototype Using Lab in a Cartridge™ Technology. Blood. 142(Supplement 1). 2290–2290. 1 indexed citations
3.
Breyer, Johannes, Markus Eckstein, Danijel Sikic, et al.. (2023). Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). Scientific Reports. 13(1). 15437–15437. 4 indexed citations
4.
Erfani, Parsa, Michael Bates, Danny A. Milner, et al.. (2022). Leveraging Molecular Diagnostic Technologies to Close the Global Cancer Pathology Gap. JCO Global Oncology. 8(8). e2200182–e2200182. 3 indexed citations
5.
6.
Filipits, Martin, Margaretha Rudas, Christian F. Singer, et al.. (2021). ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. ESMO Open. 6(4). 100228–100228. 16 indexed citations
7.
Chumsri, Saranya, Jeff Sperinde, Heshan Liu, et al.. (2018). High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research. 24(13). 3053–3058. 23 indexed citations
8.
Wasserman, Brad, Daniel Carvajal‐Hausdorf, Wendy Wong, et al.. (2017). High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence. Laboratory Investigation. 97(12). 1521–1526. 20 indexed citations
9.
Ghosh, Ritwik, Archana Narasanna, Shizhen Emily Wang, et al.. (2011). Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Research. 71(5). 1871–1882. 171 indexed citations
10.
Joensuu, Heikki, Jeff Sperinde, M. Leinonen, et al.. (2011). Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology. 22(9). 2007–2013. 20 indexed citations
11.
Desmedt, Christine, Jeff Sperinde, Fanny Piette, et al.. (2009). Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology. 18(1). 22–29. 31 indexed citations
12.
Skowron, Gail, John Spritzler, Jodi Weidler, et al.. (2009). Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 50(3). 250–258. 4 indexed citations
13.
Goetz, Matthew Bidwell, Robert Leduc, Jay R. Kostman, et al.. (2009). Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 50(3). 259–266. 42 indexed citations
14.
Viani, Rolando M., Lígia Peralta, Grace M. Aldrovandi, et al.. (2006). Prevalence of Primary HIV‐1 Drug Resistance among Recently Infected Adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study. The Journal of Infectious Diseases. 194(11). 1505–1509. 45 indexed citations
15.
Michael, Bryane & Michael Bates. (2004). Assessing International Fiscal and Monetary Transparency: The Role of Standards, Knowledge Management and Project Design. SSRN Electronic Journal. 4 indexed citations
16.
17.
Parkin, Neil, et al.. (2002). Phenotypic and Genotypic HIV-1 Drug Resistance Assays Provide Complementary Information. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(2). 128–136. 40 indexed citations
18.
Bates, Michael, John C. Bucuvalas, Marı́a Pilar Alonso, & Frederick C. Ryckman. (1998). Biliary Atresia: Pathogenesis and Treatment. Seminars in Liver Disease. 18(3). 281–293. 101 indexed citations
19.
Furlong, Michael J., et al.. (1997). Drugs and School Violence. Education and Treatment of Children. 20(3). 263–280. 39 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jōhn W. Parker Breakdown of academic impact, for papers by Barry Anderson Breakdown of academic impact, for papers by J L Sullivan Breakdown of academic impact, for papers by Eva Halapi Breakdown of academic impact, for papers by David J. DiLillo Breakdown of academic impact, for papers by M. Jean Gilbert Breakdown of academic impact, for papers by Sophia Lee Breakdown of academic impact, for papers by Alison Crawford Breakdown of academic impact, for papers by Musie Ghebremichael Breakdown of academic impact, for papers by Helen Brown
Rankless by CCL
2026